Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 154 Show results per page	View Search Criteria \| Help With Results


1.		PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				15 and over				Other				LAL-RI/96 NCT00494897

Last Modified: 3/14/2007


2.		Phase II/III Randomized Comparison of Up-Front Alternating Chemotherapy vs Up-Front Intensive 6-MP/MTX for Poor Prognosis Childhood ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 20				NCI				POG-8698

Last Modified: 4/12/2007


3.		Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 21				NCI				POG-8741/42 POG-8741, POG-8742


4.		Phase III Study with CACP vs ADR/CTX/CACP & Phase II Study with VM-26 for Disseminated Transitional Cell Urinary Tract Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 75				NCI				EST-1878

Last Modified: 7/1/1988


5.		Phase II/III Evaluation of IPP and VM-26 as Single Agents vs Combination Chemotherapy with CAV (CTX/ADR/VCR) in Patients with Extensive Small Cell Lung Cancer (Summary Last Modified 07/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				NCI				EST-1588

Last Modified: 7/1/1990


6.		Phase II/III Study of Teniposide with vs without Whole-Brain Radiotherapy in Patients with Small Cell Lung Cancer Metastatic to the Brain (Summary Last Modified 07/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				75 and under								EORTC-08891

Last Modified: 3/9/2007


7.		Phase III Randomized Study of "Iceberg" Radiotherapy vs No Further Treatment for Stage II/III/IV Intermediate- and High-Grade NHL in CR Following Chemotherapy with DOX/VM-26/CTX/PRED/VCR/BLEO or a Comparable Regimen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				50 and over								EORTC-20932

Last Modified: 5/7/2008


8.		Phase III Randomized Study of High Versus Standard Dose Methotrexate and High Dose Cytarabine and Asparaginase Rescue Versus Standard Dose Cytarabine and Teniposide During Intensive Continuation and Consolidation in Children with High Risk Acute Lymphocytic Leukemia: An ALinC #16 Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				1 to 21 at diagnosis				NCI				POG-9406 POG-ALINC-16/HR


9.		Phase III Comparison of IPP/AMSA/VP-16 vs IPP/AMSA/VM-26 in Patients with Relapsed Hodgkin's and non-Hodgkin's Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified								NCI-D81-043-156 MDA-DT-8071

Last Modified: 2/2/2007


10.		Postoperative Radiotherapy and Combination Chemotherapy with BCNU, PCB, HU, and VM-26 for Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				over 15								BTSG-8001

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute